You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
嘉和生物(06998.HK)治療類風濕性關節炎新藥上市申請獲內地批准
阿思達克 03-01 12:04
嘉和生物-B(06998.HK)公布,旗下GB242英夫利西單抗已獲中國國家藥監局批准,用於治療類風濕性關節炎、強直性脊柱 炎、銀屑病、成人潰瘍性結腸炎、成人及6歲以上兒童克羅恩病、瘺管性克羅恩病。 GB242的新藥上市申請是基於一項在中國類風濕性關節炎患者中開展的與類克(英夫利西單抗)比較的三期臨床試驗。 公司指,作為其第一個商業化藥品,GB242獲批為中國患者帶來更多治療選擇,亦為公司發展歷程中的重要里程碑。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account